Benefits of online in vivo dosimetry for single-fraction total body irradiation

Use of a patient test dose before single-fraction total body irradiation (TBI) allows review of in vivo dosimetry and modification of the main treatment setup. However, use of computed tomography (CT) planning and online in vivo dosimetry may reduce the need for this additional step. Patients were treated using a supine CT-planned extended source-to-surface distance (SSD) technique with lead compensators and bolus. In vivo dosimetry was performed using thermoluminescent dosimeters (TLDs) and diodes at 10 representative anatomical locations, for both a 0.1-Gy test dose and the treatment dose. In total, 28 patients were treated between April 2007 and July 2013, with changes made in 10 cases (36%) following test dose results. Overall, 98.1% of measured in vivo treatment doses were within 10% of the prescribed dose, compared with 97.0% of test dose readings. Changes made following the test dose could have been applied during the single-fraction treatment itself, assuming that the dose was delivered in subportions and online in vivo dosimetry was available for all clinically important anatomical sites. This alleviates the need for a test dose, saving considerable time and resources.

Accurate dosimetric measurement of large extended SSD fields for comparison to TPS models

PURPOSE

There is little evidence in the literature which quantifies the accuracy of Treatment Planning Systems (TPSs) using large fields at extended SSD (eSSD). This paper introduces the approach taken at Christchurch Hospital, New Zealand to validate the use of the Monaco TPS for Total Body Irradiation (TBI) treatments.

METHODS

A purpose-built device for allowing precise movements of block-like phantoms called a Phantom Mobility Device (PMD) was used for collecting measurements at eSSD. These measurements were used for determining the ability of the Monaco TPS (originally validated for SSDs between 80 and 110 cm) to accurately model dose distributions for TBI treatments at Christchurch Hospital on either treatment machine one (T1) or two (T2) with SSD values of 341 and 432.6 and clinically useful field sizes of 120 and 170 cm, respectively.

RESULTS

We found that within the limits of measurement uncertainty the PMD contributed no determinable scatter to the measurements and proved a reliable approach for eSSD dose measurements. Additionally, by applying depth and off-axis distance constraints of use for TPS information it is possible to use the existing Monaco CCC model at eSSD for block phantom geometries. Dose Difference (DD) analysis showed a clinically acceptable agreement between the CCC model and measured data over a range of depths and off-axis distances.

CONCLUSIONS

The PMD was determined to be a useful tool for accurate measurement of extended SSD treatment fields. Monaco TPS CCC model agreed well for block phantoms so future comparisons to anthropomorphic phantoms or patient data are feasible.